Home
Search
Policy

Intellectual Property

Intellectual property is the lifeblood of the biotechnology industry. Strong patents, and an efficient, predictable, and objective patent system, are critical to ensuring a steady stream of capital to biotechnology companies developing innovative medicines, alternative energy sources, insect- and drought-resistant crops, and a wide range of other innovative biotechnologies that are helping to feed, fuel, and heal our planet. This quintessentially-American industry leads the world in innovation, providing the United States with a global competitive advantage and spurring economic growth and the creation of high-paying jobs here at home.

IPCC_Webinar-Series-MSC
Explore What's New in Biotech IP

Biotech Intellectual Property Law in Focus is a new webinar series offering timely, relevant insights into the latest issues in the biotech intellectual property sector.  This focused webinar series will cover what's new and important in the biotech IP landscape today, featuring expert perspective and information you can put into practice the very next day. 

Learn More
IP Attaché Program

BIO works with the United States Patent and Trademark Office’s (USPTO) IP attaché program, which strives to improve Intellectual property (IP) systems internationally for the benefit of U.S. stakeholders. IP attachés are posted at U.S. missions around the world to address IP issues arising in their assigned regions. 

Find an attaché in your region
USPTO
Amicus Briefs
Browse all Amicus Briefs
BIO Files Amicus Brief in Support of Rehearing Case Addressing Patent-Eligibility of Diagnostic Technology (U.S. Court of Appeals for the Federal Circuit)
April 22, 2019
BIO files amicus brief in support of a petition for rehearing related to patent-eligibility of diagnostic technology. 
BIO Files Amicus Brief on Case Addressing the America Invents Act’s Joinder Provision
December 28, 2018
BIO files an Amicus Brief on rehearing by the Precedential Opinion Panel of the Patent Trial and Appeal Board.
BIO Files Amicus Brief on Case Addressing Unfairness or Imbalance in Post-Grant Proceedings at PTO (U.S. Court of Appeals for the Federal Circuit)
April 9, 2018
BIO and PhRMA have submitted a brief in the U.S Court of Appeals for the Federal Circuit on behalf of appellant in Virnetx Inc. v. The Mangrove Partners. 
Insights
Browse all insights
innovation-drug
Made in America Week: Celebrating America’s Vibrant Biopharma Industry
Scientist in lab
Q&A: Senator Tillis on the Vital Link Between Intellectual Property Protections & Innovation
Gavel sitting on top of a book that reads PATENT LAW
#TBT: Debunking Some Common Myths on Patent Protections
News
Browse all news
BIO’s Dr. Michelle McMurry-Heath Congratulates President-Elect Biden & Other Newly Elected Leaders of Both Parties Who Won
November 7, 2020
New Online IP Marketplace Will Foster Collaboration in Race to Eradicate COVID-19
May 4, 2020
BIO's 2020 Special 301 Submission
February 6, 2020
America’s Bioeconomy Plays Critical Role in Feeding, Fueling, and Healing the World
October 22, 2019
IPCC-logo

The BIO IP Counsels Committee Conference offers timely, relevant educational sessions on the latest issues in the biotech IP sector.  Attend informal networking events designed to promote discussion and foster relationships among industry colleagues, and learn practical tips you can put into use the next day. 

Learn More
Letters, Comments & Testimony
Browse all Letters, Comments & Testimony
BIO's 2020 Special 301 Submission
February 6, 2020
Section 182 of the Trade Act of 1974, known as the “Special 301” provisions, requires the United States Trade Representative to identify countries that deny adequate and effective intellectual property protections or fair and equitable market access to U.S. persons who rely on IP protection. As…
BIO's 2019 Special 301 Submission
March 27, 2019
Section 182 of the Trade Act of 1974, known as the “Special 301” provisions, requires the United States Trade Representative to identify countries that deny adequate and effective intellectual property protections or fair and equitable market access to U.S. persons who rely on IP protection. As…
BIO's Comment on Advanced Notice of Proposed Rulemaking Regarding Review of Controls for Certain Emerging Technologies
January 17, 2019
BIO urges the Administration to fully assess the potential impact of export controls on biotechnologies on “the impact on the economy of the United States” and on the sustainability of the U.S.’s global leadership in biotechnology, and pursue them “only to the extent necessary” to ensure national…
Patient-Take-Action
Become an Advocate for Biotechnology

Sign-up to join BIOAction, BIO's grassroots advocacy program. You will be notified about relevant policy issues where we need you to contact your lawmaker.

Join BIOAction